Marc Carrier Selected Research

apixaban

4/2024	Primary prevention of venous thromboembolism in ambulatory cancer patients: recent advances and practical implications.
7/2023	Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.
1/2023	Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.
1/2022	Growth differentiation factor-15 for prediction of bleeding in cancer patients.
1/2022	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
1/2022	Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
1/2022	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.
12/2021	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial.
10/2021	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
4/2021	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Carrier Research Topics

Disease

106	Neoplasms (Cancer) 05/2024 - 01/2008
96	Venous Thromboembolism 05/2024 - 12/2002
92	Hemorrhage 05/2024 - 05/2010
51	Thrombosis (Thrombus) 11/2023 - 01/2003
26	Venous Thrombosis (Deep-Vein Thrombosis) 09/2023 - 01/2003
17	Pulmonary Embolism 01/2023 - 01/2006
16	COVID-19 01/2022 - 01/2020
13	Atrial Fibrillation 11/2023 - 09/2011
11	Thrombocytopenia (Thrombopenia) 01/2023 - 01/2007
7	Critical Illness (Critically Ill) 01/2022 - 08/2016
6	Obesity 03/2024 - 01/2020
6	Thromboembolism 01/2022 - 01/2018
5	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 11/2020 - 12/2002
4	Stroke (Strokes) 11/2023 - 06/2014
4	Neoplasm Metastasis (Metastasis) 02/2023 - 07/2013
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2022 - 08/2018
3	Upper Extremity Deep Vein Thrombosis 12/2023 - 02/2015
3	Thrombophilia 11/2023 - 06/2010
3	Infections 01/2022 - 07/2020
3	Subacute Sclerosing Panencephalitis (SSPE) 11/2020 - 12/2017
3	Pregnancy Complications 02/2014 - 06/2010
2	Vascular System Injuries 09/2023 - 02/2014
2	Leukemia 07/2023 - 12/2020
2	Wounds and Injuries (Trauma) 01/2023 - 01/2022
2	Urinary Bladder Neoplasms (Bladder Cancer) 10/2022 - 01/2022
2	Sepsis (Septicemia) 01/2022 - 06/2017
2	Inflammation (Inflammations) 01/2022 - 07/2021
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2014
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 12/2016
2	Embolism (Embolus) 11/2019 - 06/2014
2	Chronic Disease (Chronic Diseases) 01/2019 - 10/2018
2	Abruptio Placentae (Placental Abruption) 07/2011 - 06/2010
2	Pre-Eclampsia (Preeclampsia) 07/2011 - 06/2010
1	Spinal Injuries (Spinal Injury) 03/2024
1	Thromboinflammation 09/2023

Drug/Important Bio-Agent (IBA)

106	AnticoagulantsIBA 04/2024 - 02/2009
54	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 05/2024 - 01/2003
26	apixabanIBA 04/2024 - 08/2013
23	RivaroxabanIBA 05/2024 - 08/2013
19	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 01/2003
14	Vitamin K FDA Link 10/2022 - 08/2013
10	fibrin fragment D (D-dimer)IBA 01/2022 - 01/2006
9	Dalteparin (Dalteparin Sodium)FDA Link 12/2021 - 06/2013
9	edoxabanIBA 12/2021 - 06/2014
7	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2020
7	Factor Xa InhibitorsIBA 07/2023 - 11/2015
7	Warfarin (Coumadin)FDA LinkGeneric 07/2021 - 09/2009
7	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2020 - 06/2013
6	Dabigatran FDA Link 03/2021 - 08/2013
5	Prothrombin (Factor II)IBA 11/2023 - 06/2010
5	Hemostatics (Antihemorrhagics)IBA 07/2023 - 11/2020
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 08/2013
3	factor V LeidenIBA 11/2023 - 12/2002
3	prothrombin complex concentrates (PPSB)IBA 07/2023 - 11/2020
3	Thrombin FDA Link 07/2023 - 01/2023
3	VaccinesIBA 01/2023 - 01/2021
3	AntibodiesIBA 01/2023 - 01/2007
3	CreatinineIBA 01/2022 - 07/2015
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 03/2021
3	ORALIT (ORS)IBA 12/2021 - 06/2010
3	Fondaparinux (Arixtra)FDA Link 01/2021 - 09/2014
2	Enoxaparin (Lovenox)FDA LinkGeneric 01/2023 - 08/2016
2	COVID-19 VaccinesIBA 01/2023 - 01/2022
2	C-Reactive ProteinIBA 01/2023 - 01/2022
2	Immune Checkpoint InhibitorsIBA 01/2023 - 09/2021
2	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/2023 - 01/2023
2	Troponin T (Troponin T1)IBA 07/2022 - 04/2013
2	pro-brain natriuretic peptide (1-76)IBA 07/2022 - 04/2013
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 03/2022 - 01/2022
2	Tinzaparin (Innohep)FDA Link 01/2022 - 12/2011
2	Oxygen (Dioxygen)IBA 01/2022 - 04/2017
2	Fibrinogen (Factor I)FDA Link 07/2021 - 03/2021
2	Asparaginase (Elspar)FDA Link 12/2020 - 01/2020
2	Neutralizing AntibodiesIBA 10/2020 - 07/2020
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 07/2020 - 06/2014
2	AntithrombinsIBA 01/2020 - 01/2019
2	Nadroparin (Nadroparin Calcium)IBA 01/2020 - 12/2016
2	coumarinIBA 05/2019 - 07/2012
2	boldenone undecylenate (Equipoise)IBA 01/2017 - 01/2015
1	Tranexamic Acid (AMCA)FDA Link 03/2024
1	fibrinogen gamma'IBA 11/2023
1	SerpinsIBA 11/2023
1	InflammasomesIBA 09/2023
1	Colchicine FDA LinkGeneric 09/2023
1	canakinumab FDA Link 09/2023

Therapy/Procedure

67	Therapeutics 04/2024 - 01/2003
35	Drug Therapy (Chemotherapy) 11/2023 - 02/2012
8	Catheters 12/2023 - 09/2012
7	Central Venous Catheters 12/2023 - 02/2015
6	Contraindications 01/2022 - 02/2012
4	Duration of Therapy 07/2022 - 02/2012
4	Artificial Respiration (Mechanical Ventilation) 01/2022 - 10/2020
3	Secondary Prevention 04/2017 - 08/2013
2	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2023 - 01/2018
2	Cystectomy 01/2022 - 01/2017
2	Immunotherapy 01/2022 - 01/2021
2	Erythrocyte Transfusion 03/2021 - 10/2020
2	Platelet Transfusion (Blood Platelet Transfusions) 12/2020 - 10/2018
2	Bariatric Surgery 01/2020 - 04/2014
1	Aftercare (After-Treatment) 01/2023